Exelixis | EXEL - Gross Profit On Sales



Exelixis reported $548.79M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.83M 19.91M Jun/2025
Agios Pharmaceuticals USD 10.75M 3.11M Jun/2025
Amgen USD 6.17B 624M Jun/2025
AstraZeneca USD 11.98B 637M Jun/2025
Bayer EUR 6.38B 1.74B Jun/2025
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Cytokinetics 66.77M 165.03M Jun/2025
Eisai JPY 160.05B 12.42B Jun/2025
Eli Lilly USD 13.11B 2.61B Jun/2025
Exelixis USD 548.79M 12.52M Jun/2025
Genmab DKK 868M 195M Jun/2025
Glaxosmithkline GBP 5.83B 232M Jun/2025
Incyte USD 1.14B 151.67M Jun/2025
Ionis Pharmaceuticals USD 448M 317.85M Jun/2025
MacroGenics USD -27460000 41.32M Jun/2025
Merck USD 12.99B 224M Jun/2025
Moderna USD 18M 1000K Jun/2025
Neurocrine Biosciences USD 676.2M 112.8M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Sanofi EUR 7.74B 2.38B Jun/2025
Takeda JPY 722.01B 50.69B Jun/2025
Ultragenyx Pharmaceutical USD 143.49M 32.86M Jun/2025
Xencor 43.61M 10.88M Jun/2025